Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Deloitte
Johnson and Johnson
Argus Health
Medtronic
Novartis
AstraZeneca
Colorcon
Harvard Business School
Dow
Teva

Generated: February 22, 2018

DrugPatentWatch Database Preview

Details for Patent: 9,421,333

« Back to Dashboard

Which drugs does patent 9,421,333 protect, and when does it expire?

Patent 9,421,333 protects OTREXUP and is included in one NDA.

This patent has twelve patent family members in seven countries.
Summary for Patent: 9,421,333
Title:Hazardous agent injection system
Abstract: Injection systems comprising a powered injector and one or more hazardous agents are disclosed.
Inventor(s): Wotton; Paul K. (Newton, PA), Sadowski; Peter L. (Woodbury, MN), Hayes; John W. (Chaska, MN)
Assignee: Antares Pharma, Inc. (Ewing, NJ)
Application Number:14/582,411
Patent Claim Types:
see list of patent claims
Dosage form; Use;

Drugs Protected by US Patent 9,421,333

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Antares Pharma Inc OTREXUP methotrexate SOLUTION;SUBCUTANEOUS 204824-005 Nov 7, 2014 DISCN Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y SUBCUTANEOUS INJECTION OF METHOTREXATE ➤ Try a Free Trial
Antares Pharma Inc OTREXUP methotrexate SOLUTION;SUBCUTANEOUS 204824-001 Oct 11, 2013 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y SUBCUTANEOUS INJECTION OF METHOTREXATE ➤ Try a Free Trial
Antares Pharma Inc OTREXUP methotrexate SOLUTION;SUBCUTANEOUS 204824-006 Mar 24, 2016 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y SUBCUTANEOUS INJECTION OF METHOTREXATE ➤ Try a Free Trial
Antares Pharma Inc OTREXUP methotrexate SOLUTION;SUBCUTANEOUS 204824-002 Oct 11, 2013 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y SUBCUTANEOUS INJECTION OF METHOTREXATE ➤ Try a Free Trial
Antares Pharma Inc OTREXUP methotrexate SOLUTION;SUBCUTANEOUS 204824-007 Mar 24, 2016 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y SUBCUTANEOUS INJECTION OF METHOTREXATE ➤ Try a Free Trial
Antares Pharma Inc OTREXUP methotrexate SOLUTION;SUBCUTANEOUS 204824-003 Oct 11, 2013 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y SUBCUTANEOUS INJECTION OF METHOTREXATE ➤ Try a Free Trial
Antares Pharma Inc OTREXUP methotrexate SOLUTION;SUBCUTANEOUS 204824-008 Mar 24, 2016 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y SUBCUTANEOUS INJECTION OF METHOTREXATE ➤ Try a Free Trial
Antares Pharma Inc OTREXUP methotrexate SOLUTION;SUBCUTANEOUS 204824-004 Oct 11, 2013 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y SUBCUTANEOUS INJECTION OF METHOTREXATE ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 9,421,333

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,480,631 Hazardous agent injection system ➤ Try a Free Trial
9,750,881 Hazardous agent injection system ➤ Try a Free Trial
8,579,865 Hazardous agent injection system ➤ Try a Free Trial
8,945,063 Hazardous agent injection system ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 9,421,333

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2010226442 ➤ Try a Free Trial
Canada 2755779 ➤ Try a Free Trial
China 102612381 ➤ Try a Free Trial
European Patent Office 2408493 ➤ Try a Free Trial
Japan 2012521224 ➤ Try a Free Trial
Japan 2015042270 ➤ Try a Free Trial
Japan 2016104214 ➤ Try a Free Trial
Japan 5732039 ➤ Try a Free Trial
Japan 5968976 ➤ Try a Free Trial
South Korea 101597672 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Department of Justice
Boehringer Ingelheim
US Army
Baxter
Cantor Fitzgerald
Dow
Citi
Merck
Daiichi Sankyo

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot